Anticancer effects of marine carotenoids, fucoxanthin and its deacetylated product, fucoxanthinol, on osteosarcoma

Rokkaku,Takayoshi; Kimura,Ryuichiro; Ishikawa,Chie; Yasumoto,Takeshi; Senba,Masachika; Kanaya,Fuminori; Mori,Naoki

doi:10.3892/ijo.2013.2019

Anticancer effects of marine carotenoids, fucoxanthin and its deacetylated product, fucoxanthinol, on osteosarcoma

Authors:
- Takayoshi Rokkaku
- Ryuichiro Kimura
- Chie Ishikawa
- Takeshi Yasumoto
- Masachika Senba
- Fuminori Kanaya
- Naoki Mori
View Affiliations

Affiliations: Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan, Marine Bio Industry Division, Okinawa Science and Technology Promotion Center, Naha, Okinawa 900-0029, Japan, Department of Pathology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan, Department of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan
Published online on: July 15, 2013 https://doi.org/10.3892/ijo.2013.2019
Pages: 1176-1186

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Survival of osteosarcoma patients hinges on prevention or treatment of recurrent and metastatic lesions. Therefore, novel chemotherapeutics for more effective treatment and prevention of this disease are required. Carotenoids are natural pigments and exhibit various biological functions. We evaluated the anti-osteosarcoma properties of several carotenoids. Among carotenoids, fucoxanthin and its metabolite fucoxanthinol, inhibited the cell viability of osteosarcoma cell lines. Fucoxanthinol induced G1 cell cycle arrest by reducing the expression of cyclin-dependent kinase 4, cyclin-dependent kinase 6 and cyclin E and apoptosis by reducing the expression of survivin, XIAP, Bcl-2 and Bcl-xL. Apoptosis was associated with activation of caspases-3, -8 and -9. In addition, fucoxanthinol inhibited the phosphorylation of phosphoinositide-dependent kinase 1 and Akt and the downstream glycogen synthase kinase 3β, resulting in downregulation of β-catenin. Fucoxanthinol inhibited the cell migration and invasion of osteosarcoma cells. It also reduced matrix metalloproteinase-1 expression and the activator protein-1 signal. Treatment of mice inoculated with osteosarcoma cells with fucoxanthin inhibited the development of osteosarcoma in mice. Fucoxanthin and fucoxanthinol inhibit cell growth, migration and invasion and induce apoptosis of osteosarcoma cells at least in part by inhibiting Akt and activator protein-1 pathways. Our findings provide a rationale for clinical evaluation of these novel agents in osteosarcoma.

View Figures

View References

1.	Savage S and Mirabello L: Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011:5481512011. View Article : Google Scholar : PubMed/NCBI
2.	Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AHM, Hogendoorn PCW and Egeler RM: Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
3.	Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Musa-Veloso K, Card JW, Wong AW and Cooper DA: Influence of observational study design on the interpretation of cancer risk reduction by carotenoids. Nutr Rev. 67:527–545. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Peng J, Yuan J-P, Wu C-F and Wang J-H: Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health. Mar Drugs. 9:1806–1828. 2011. View Article : Google Scholar : PubMed/NCBI
6.	Yamamoto K, Ishikawa C, Katano H, Yasumoto T and Mori N: Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas. Cancer Lett. 300:225–234. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Rhim JS, Putman DL, Arnstein P, Huebner RJ and McAllister RM: Characterization of human cells transformed in vitro by N-methyl-N′-nitro-N-nitrosoguanidine. Int J Cancer. 19:505–510. 1977.
8.	Hensler PJ, Annab LA, Barrett JC and Pereira-Smith OM: A gene involved in control of human cellular senescence on human chromosome 1q. Mol Cell Biol. 14:2291–2297. 1994. View Article : Google Scholar : PubMed/NCBI
9.	Zhang C, Ao Z, Seth A and Schlossman SF: A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J Immunol. 157:3980–3987. 1996.PubMed/NCBI
10.	Antalis TM and Godbolt D: Isolation of intact nuclei from hematopoietic cell types. Nucleic Acids Res. 19:43011991. View Article : Google Scholar : PubMed/NCBI
11.	Mori N and Prager D: Transactivation of the interleukin-1α promoter by human T-cell leukemia virus type I and type II Tax proteins. Blood. 87:3410–3417. 1996.
12.	Sherr CJ and Roberts JM: Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Cheng L, Rossi F, Fang W, Mori T and Cobrinik D: Cdk2-dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(−), p16^INK4A(+) tumor cells. J Biol Chem. 275:30317–30325. 2000.PubMed/NCBI
14.	Perkins ND: The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132. 2012.
15.	Hayden MS and Ghosh S: Shared principles in NF-κB signaling. Cell. 132:344–362. 2008.
16.	Iwanaga R, Ohtani K, Hayashi T and Nakamura M: Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene. 20:2055–2067. 2001. View Article : Google Scholar
17.	Zahradka P, Werner JP, Buhay S, Litchie B, Helwer G and Thomas S: NF-κB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol. 34:1609–1621. 2002.
18.	Zhu L, Fukuda S, Cordis G, Das DK and Maulik N: Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. FEBS Lett. 508:369–374. 2001. View Article : Google Scholar
19.	Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR and Lipp J: Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. J Exp Med. 188:211–216. 1998.
20.	Pahl HL: Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 18:6853–6866. 1999.
21.	Grossmann M, O’Reilly LA, Gugasyan R, Strasser A, Adams JM and Gerondakis S: The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J. 19:6351–6360. 2000. View Article : Google Scholar : PubMed/NCBI
22.	Nicot C, Mahieux R, Takemoto S and Franchini G: Bcl-X_L is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood. 96:275–281. 2000.PubMed/NCBI
23.	Jin S, Pang R-P, Shen J-N, Huang G, Wang J and Zhou J-G: Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells. Apoptosis. 12:1317–1326. 2007. View Article : Google Scholar : PubMed/NCBI
24.	Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI
25.	Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, Surrenti N, Sangiolo D, Bussolino F, Piacibello W and Aglietta M: Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res. 11:490–497. 2005.PubMed/NCBI
26.	Kimura R, Ishikawa C, Rokkaku T, Janknecht R and Mori N: Phosphorylated c-Jun and Fra-1 induce matrix metalloproteinase-1 and thereby regulate invasion activity of 143B osteosarcoma cells. Biochim Biophys Acta. 1813:1543–1553. 2011. View Article : Google Scholar : PubMed/NCBI
27.	Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S and Yoshikawa H: Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer. 76:418–422. 1998. View Article : Google Scholar : PubMed/NCBI
28.	Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB: NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 401:82–85. 1999.
29.	Ali NN, Gilston V and Winyard PG: Activation of NF-κB in human osteoblasts by stimulators of bone resorption. FEBS Lett. 460:315–320. 1999.
30.	Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang H-G, Tsang BK and Cheng JQ: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem. 279:5405–5412. 2004. View Article : Google Scholar : PubMed/NCBI
31.	Liang Y-L, Wang L-Y, Wu H, Ma D-Z, Xu Z and Zha X-L: PKB phosphorylation and survivin expression are cooperatively regulated by disruption of microfilament cytoskeleton. Mol Cell Biochem. 254:257–263. 2003. View Article : Google Scholar : PubMed/NCBI
32.	Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE and Reusch JE-B: Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 275:10761–10766. 2000. View Article : Google Scholar : PubMed/NCBI
33.	Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
34.	Gialeli G, Theocharis AD and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar : PubMed/NCBI
35.	Jawad MU, Garamszegi N, Garamszegi SP, Correa-Medina M, Diez JA, Wen R and Scully SP: Matrix metalloproteinase 1: role in sarcoma biology. PLoS One. 5:e142502010. View Article : Google Scholar : PubMed/NCBI